BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amitrano L, Guardascione MA, Ames PR, Margaglione M, Antinolfi I, Iannaccone L, Annunziata M, Ferrara F, Brancaccio V, Balzano A. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003;72:75-81. [PMID: 12555209 DOI: 10.1002/ajh.10254] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, Chiusolo P, Sica S, Leone G. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica 2009;94:733-7. [PMID: 19336736 DOI: 10.3324/haematol.13869] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
2 Trifa AP, Cucuianu A, Popp RA, Coadă CA, Costache RM, Militaru MS, Vesa ŞC, Pop IV. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia. Ann Hematol 2014;93:203-9. [PMID: 23828072 DOI: 10.1007/s00277-013-1838-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
3 Rössle M MD, Schultheiss M. Timing of the Treatment of Portal Vein Thrombosis in Patients with Cirrhosis: A German Hepatologist's Perspective. J Transl Int Med 2018;6:11-5. [PMID: 29607298 DOI: 10.2478/jtim-2018-0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Vassiliadis T, Mpoumponaris A, Giouleme O, Hatzidakis A, Patsiaoura K, Zezos P, Vakalopoulou S, Kargiotis K, Gkisakis D, Katsinelos P, Evgenidis N. Late onset ulcerative colitis complicating a patient with Budd-Chiari syndrome: a case report and review of the literature. Eur J Gastroenterol Hepatol 2009;21:109-13. [PMID: 19060635 DOI: 10.1097/MEG.0b013e32830263cb] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013;162:730-47. [PMID: 23855810 DOI: 10.1111/bjh.12461] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
6 Parashar Y, Kushwaha R, Kumar A, Agarwal K, Singh US, Jain M, Verma SP, Tripathi AK. Haemostatic Profile in Patients of Myeloproliferative Neoplasms-A Tertiary Care Centre Experience. J Clin Diagn Res 2016;10:EC01-4. [PMID: 28050371 DOI: 10.7860/JCDR/2016/19985.8840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Rusak T, Ciborowski M, Uchimiak-owieczko A, Piszcz J, Radziwon P, Tomasiak M. Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: The effect of isovolemic erythrocytapheresis. Platelets 2011;23:455-62. [DOI: 10.3109/09537104.2011.633178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
8 Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, Gatti L, Mannucci PM, Peyvandi F. Global coagulation in myeloproliferative neoplasms. Ann Hematol 2013;92:1633-9. [DOI: 10.1007/s00277-013-1834-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
9 Marchetti M, Castoldi E, Spronk HMH, van Oerle R, Balducci D, Barbui T, Rosing J, ten Cate H, Falanga A. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008;112:4061-8. [DOI: 10.1182/blood-2008-06-164087] [Cited by in Crossref: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
10 Sergueeva AI, Miasnikova GY, Okhotin DJ, Levina AA, Debebe Z, Ammosova T, Niu X, Romanova EA, Nekhai S, DiBello PM, Jacobsen DW, Prchal JT, Gordeuk VR. Elevated homocysteine, glutathione and cysteinylglycine concentrations in patients homozygous for the Chuvash polycythemia VHL mutation. Haematologica 2008;93:279-82. [PMID: 18223282 DOI: 10.3324/haematol.11851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
11 Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention. Best Practice & Research Clinical Haematology 2006;19:617-33. [DOI: 10.1016/j.beha.2005.07.011] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
12 Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275-290. [PMID: 15667529 DOI: 10.1111/j.1365-2141.2004.05277.x] [Cited by in Crossref: 309] [Cited by in F6Publishing: 242] [Article Influence: 19.3] [Reference Citation Analysis]
13 Schwarz J, Ovesná P, Černá O, Kissová J, Soukupová JM, Brychtová Y, Doubek M, Červinek L, Cmunt E, Dulíček P, Campr V, Křen L, Penka M; for CZEMP – Czech Group for Ph‐ Myeloproliferative Disorders. Thrombosis in thrombocythemic Ph‐ myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. Eur J Haematol 2016;96:98-106. [DOI: 10.1111/ejh.12554] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
14 Lapecorella M, Tabilio A, Lucchesi A, Napolitano M, Colagrande M, Di Ianni M, Mariani G. Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment. Blood Coagulation & Fibrinolysis 2008;19:453-7. [DOI: 10.1097/mbc.0b013e3283079e46] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Peerschke EI, Silver RT, Weksler B, Grigg SE, Savion N, Varon D. Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists. Br J Haematol 2004;127:195-203. [PMID: 15461626 DOI: 10.1111/j.1365-2141.2004.05190.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ames PRJ, Di Girolamo G, D'Andrea G, Lopez LR, Gaeta G, Iannaccone L, Maraglione M. Predictive Value of Oxidized Low-Density Lipoprotein/β2-Glycoprotein-I Complexes (oxLDL/β2GPI) in Nonautoimmune Atherothrombosis. Clin Appl Thromb Hemost 2018;24:1050-5. [PMID: 29669439 DOI: 10.1177/1076029618767752] [Reference Citation Analysis]
17 Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell’Era A, Bucciarelli P, Mannucci PM. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528-1534. [PMID: 17133457 DOI: 10.1002/hep.21435] [Cited by in Crossref: 176] [Cited by in F6Publishing: 142] [Article Influence: 12.6] [Reference Citation Analysis]
18 Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Seminars in Hematology 2004;41:10-4. [DOI: 10.1053/j.seminhematol.2004.02.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
19 Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006;77:327-33. [PMID: 16856928 DOI: 10.1111/j.1600-0609.2006.00715.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
20 El-Ghonemy MS, El Sharawy S, Fahmi MW, El-Ashwah S, Denewer M, El-Baiomy MA. Thrombophilic Risk of Factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin Mutations in Essential Thrombocythemia Egyptian Patients. Adv Hematol 2020;2020:7695129. [PMID: 32292481 DOI: 10.1155/2020/7695129] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Lazareth I, Delarue R, Priollet P. Quand évoquer un syndrome myéloprolifératif en pathologie vasculaire ? Journal des Maladies Vasculaires 2005;30:46-52. [DOI: 10.1016/s0398-0499(05)83794-1] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
22 Vayá A, Plumé G, Bonet E, Carrasco P, Morales-suárez-varela MM. Hyperhomocysteinemia and the methylene tetrahydrofolate reductase C677T mutation in splanchnic vein thrombosis: Hyperhomocysteinemia and MTHFR mutation. European Journal of Haematology 2011;86:167-72. [DOI: 10.1111/j.1600-0609.2010.01551.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
23 Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Reviews 2010;24:227-32. [DOI: 10.1016/j.blre.2010.08.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
24 Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008;22:2020-8. [DOI: 10.1038/leu.2008.253] [Cited by in Crossref: 91] [Cited by in F6Publishing: 72] [Article Influence: 7.0] [Reference Citation Analysis]
25 Kornblihtt L, Heller P, Correa G, Castañón M, Genoud V, Vassallu P, Sarano J, Kordich L, Molinas F. Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations. Thrombosis Research 2003;112:131-5. [DOI: 10.1016/j.thromres.2003.11.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]